Community Benefit of No-charge Calcium Score Screening Program
Overview
Current approaches in primary prevention for cardiovascular disease are based on probabilistic approaches to estimate risk, using many of the widely available cardiovascular risks scores, with over 100 such scoring systems currently available throughout the world. The rationale for this practice is to select those individuals at greatest risk for more intense targets, reduce risk of treatment to those at minimal risk, and to maximize the cost-effectiveness of treatment. A recent Cochrane Systematic Review assessed the practice of using risk scores to select individuals for the primary prevention of cardiovascular disease. 3 The principal finding of the systematic review was that there was little or no effect of providing clinicians with cardiovascular risk scores when compared to standard of care (5.4% versus 5.3%; relative risk 1.01, 95% confidence intervals 0.95 to 1.08). The authors concluded that there is major uncertainty whether current strategies for providing risk scores and called for further research to address this concern. Extent of coronary artery calcium (CAC) is a strong risk marker for coronary events, with evidence mainly derived from observational studies and from prospective non-randomized studies. CAC, although endorsed for intermediate risk patients, is not widely adopted due to barriers in reimbursement. The cost of the test ranges between 100 and 300 USD in the United States, which may have limited the wide adoption of the test. Whether reducing the cost burden for CAC increases utilization for routine screening and its influence on physician practices and downstream testing is largely unknown. University Hospitals started offering low charge CAC (99$) since 2014. In 2017, University Hospitals started offering CAC for no charge for patients to improve access to this test, which has not traditionally been covered by insurance companies. The impact of no-charge CAC has never been studied.
Study Type
- Study Type: Observational [Patient Registry]
- Study Design
- Time Perspective: Other
- Study Primary Completion Date: December 2030
Arms, Groups and Cohorts
- Low charge CAC
- Patients receiving CAC for Cardiovascular disease risk screening at low charge (99 USD)
- No charge CAC
- Patients receiving CAC for Cardiovascular disease risk screening at no charge
Clinical Trial Outcome Measures
Primary Measures
- Statin Prescription
- Time Frame: 1 year
Secondary Measures
- Non-invasive coronary ischemia testing
- Time Frame: 1 year
- Stress echocardiograms, myocardial perfusion imaging
- Invasive coronary ischemia testing
- Time Frame: 1 year
- Invasive coronary angiography
- Coronary revascularization procedures
- Time Frame: 1 year
- Percutaneous coronary interventions, coronary artery bypass grafting
Participating in This Clinical Trial
Inclusion Criteria
- Received Coronary Artery Calcium (CAC) CT scan at University Hospitals starting in January 1, 2014. Exclusion Criteria:
-
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 100 Years
Investigator Details
- Lead Sponsor
- University Hospitals Cleveland Medical Center
- Provider of Information About this Clinical Study
- Principal Investigator: Sanjay Rajagopalan, Division Chief of Cardiovascular Medicine – University Hospitals Cleveland Medical Center
- Overall Contact(s)
- Sadeer Al-Kindi, M.D., 2168441000, sadeer.alkindi@uhhospitals.org
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.